NH TherAguix receives FDA Fast Track designation
This new designation marks an important regulatory milestone for NH TherAguix, paving the way for accelerated development of its lead drug candidate, and is in line with the deployment of the company's new development strategy, following the recent appointment of Vincent Carrère as CEO.
- This new designation marks an important regulatory milestone for NH TherAguix, paving the way for accelerated development of its lead drug candidate, and is in line with the deployment of the company's new development strategy, following the recent appointment of Vincent Carrère as CEO.
- Last September, Vincent joined NH TherAguix to lead the final steps of AGuIX® clinical developments through registration trials, until expected market approval.
- “We are delighted to have received this FDA Fast Track designation for AGuIX® in the treatment of malignant glioma.
- This Fast Track designation will facilitate NH TherAguix more frequent interactions with the FDA as well as accelerated approval and priority review in glioblastoma indications.